Friday, November 16, 2018

Mental health stigma dissipates, but cost and coverage barriers remain

More than half of Americans want mental health services either for themselves or for a loved one, but about three-quarters said there are access...

ACOs reluctant to move to advanced risk-taking models

Accountable care organizations choose their risk levels in the Medicare Shared Savings Program, and few are willing to assume more risk at this time. Modern...

Bold Moves: Risking revenue and relearning your job

This new monthly column highlights Bold Moves made by the industry's top executives. Dr. Marc Harrison, CEO of Intermountain Healthcare, suggested to us that...

Trump proposes considering public benefit use in immigration applications

Hundreds of thousands of low-income children and other members of low-income legal immigrant families could drop out of public programs providing healthcare, nutrition and...

Ascension’s TriMedx to buy Aramark’s healthcare tech business for $300M

The deal will allow TriMedx, which is owned by Ascension, to expand its healthcare clientele and Aramark to focus on its core food, facilities...

CMS underestimated Medicare ACOs’ savings

The Medicare Shared Savings program generated $ 1.84 billion in savings over a three-year period, which is nearly twice the savings CMS data...

Health systems driving prices higher with physician group purchases

The percentage of hospital-employed physicians increased from about 25% in 2010 to more than 40% in 2016, which is associated with a 12% increase...

CMS to implement indication-based drug coverage for Medicare Part D plans

Starting in 2020, Medicare Part D plans can tweak their formularies so that different drugs can be covered for a defined set of indications,...

Maine Supreme Court orders Medicaid expansion to go forward

In a largely procedural decision, Maine's high court ruled that Republican Gov. Paul LePage's administration must move forward and implement the state's voter-mandated Medicaid...

Officials remove special rules for gene therapy experiments

A special National Institutes of Health oversight panel will no longer review all gene therapy applications and will instead take on a broader advisory...
- Advertisement -

LATEST NEWS

MUST READ